Felbamate NDC 51672-4172

NDC codes

FDA NDC Directory

Product NDC (as listed)51672-4172Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51672-4172Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51672-4172-1	51672417201	237 mL in 1 BOTTLE (51672-4172-1)Marketed from Jun 16, 2017
51672-4172-9	51672417209	473 mL in 1 BOTTLE (51672-4172-9)Marketed from Jun 16, 2017

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Felbamate
Generic name (nonproprietary): felbamate
Active ingredients: Felbamate — 600 mg/5mL
Dosage form: Suspension
Route: Oral
Labeler: Sun Pharmaceutical Industries, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 206314
Marketing start: Jun 16, 2017
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 51672-4172_569a1960-5eb0-3efa-e063-6394a90a1c1eSPL ID 569a1960-5eb0-3efa-e063-6394a90a1c1eSPL set ID 0afffb17-e6ac-4bea-a90e-7ef3c8150290RxCUI 310285UNII X72RBB02N8
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451672417201 followed by a unit qualifier and the quantity

Package 51672-4172-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 14, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Felbamate oral suspension, USP is not indicated as a first line antiepileptic treatment (see Warnings ). Felbamate oral suspension is recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgement, felbamate can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epileps…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 206314

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 206314
Product	Strength	Form · route	Labeler	Product NDC
Felbamate	Felbamate 600 mg/5mL	SuspensionOral	NORTHSTAR RX LLC	16714-775